Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline

J Oncol Pract. 2015 Mar;11(2):135-6. doi: 10.1200/JOP.2014.002303. Epub 2014 Dec 16.

Authors

Natasha Rekhtman¹, Natasha B Leighl¹, Mark R Somerfield¹

Affiliation

¹ Memorial Sloan Kettering Cancer Center, New York, NY; Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and American Society of Clinical Oncology, Alexandria, VA.

PMID: 25515718
DOI: 10.1200/JOP.2014.002303

No abstract available

Publication types

Guideline

MeSH terms

Anaplastic Lymphoma Kinase
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*
Medical Oncology
Pathology, Clinical
Pathology, Molecular
Protein Kinase Inhibitors / therapeutic use*
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
Receptor Protein-Tyrosine Kinases / genetics*
Societies, Medical
United States

Substances

Protein Kinase Inhibitors
ALK protein, human
Anaplastic Lymphoma Kinase
EGFR protein, human
ErbB Receptors
Receptor Protein-Tyrosine Kinases